[1] Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma--an update[J]. CA Cancer J Clin, 2015, 65(5): 401-421.
[2] Zhong LP, Zhang CP, Ren GX, et al. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma[J]. Oncotarget, 2015, 6(21): 18707-18714.
[3] Kettle JG, Alwan H, Bista M, et al. Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival[J]. J Med Chem, 2016, 59(6): 2346-2361.
[4] Svensson LM, Jemth AS, Desroses M, et al. Crystal structure of human MTH1 and the 8-oxo-dGMP product complex[J]. FEBS Lett, 2011, 585(16): 2617-2621.
[5] Akiyama S, Saeki H, Nakashima Y, et al. Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma[J]. Cancer Med, 2017, 6(1): 258-266.
[6] Nakabeppu Y, Kajitani K, Sakamoto K, et al. MTH1, an oxidized purine nucleoside triphosphatase, prevents the cytotoxicity and neurotoxicity of oxidized purine nucleotides[J]. DNA Repair (Amst), 2006, 5(7): 761-772.
[7] Gad H, Koolmeister T, Jemth AS, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool[J]. Nature, 2014, 508(7495): 215-221.
[8] Kennedy CH, Pass HI, Mitchell JB. Expression of human MutT homologue (hMTH1) protein in primary non-small-cell lung carcinomas and histologically normal surrounding tissue[J]. Free Radic Biol Med, 2003, 34(11): 1447-1457.
[9] Okamoto K, Toyokuni S, Kim WJ, et al. Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma:
evidence of persistent oxidative stress in cancer.[J] Int J Cancer, 1996, 65(4): 437-441.
[10] Iida T, Furuta A, Kawashima M, et al. Accumulation of 8-oxo-2'-deoxyguanosine and increased expression of hMTH1 protein in brain tumors[J]. Neuro Oncol, 2001, 3(2): 73-81.
[11] Song WJ, Jiang P, Cai JP, et al. Expression of Cytoplasmic 8-oxo-Gsn and MTH1 Correlates with Pathological Grading in Human Gastric Cancer[J]. Asian Pac J Cancer Prev, 2015, 16(15): 6335-6338.
[12] Huang SH, O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer[J]. Curr Treat Options Oncol, 2017, 18(7): 40: 1-13.
[13] Saleh A, Gokturk C, Warpman-Berglund U, et al. Development and validation of method for TH588 and TH287, potent MTH1 inhibitors and new anti-cancer agents, for pharmacokinetic studies in mice plasma[J]. J Pharm Biomed Anal, 2015, 104: 1-11.
[14] Wang M, Zhou S, Chen Q, et al. Understanding the molecular mechanism for the differential inhibitory activities of compounds against MTH1[J]. Sci Rep, 2017, 7: 40557: 1-12.
[15] Li X, Li L, Huang Y, et al. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma[J]. Biomater Sci, 2017, 5(10): 2068-2078.
[16] Giribaldi MG, Munoz A, Halvorsen K, et al. MTH1 expression is required for effective transformation by oncogenic HRAS[J]. Oncotarget, 2015, 6(13): 11519-11529.
|